I don't see TONE being that expensive a trial to run. A dermbration treatment averages between $150-300 in US. Vitiligo may be a bit more expansive than normal, so $5k per patient on the extremely conservative side. 100 patients, 100 kits at cost, $350k + $500k for treatment and follow up. Throw in $2M for data and documentation work. Spread out over 6 quarters you are looking at $500k per quarter. Pretty cheap clinical trial. Which should get them what they really need, vitiligo coverage by private insurers.
- Forums
- ASX - By Stock
- Ann: AVITA Medical Q3 Revenue & Secures $90M Non-Dilutive Debt
I don't see TONE being that expensive a trial to run. A...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.82 |
Change
0.140(5.22%) |
Mkt cap ! $196.0M |
Open | High | Low | Value | Volume |
$2.78 | $2.86 | $2.77 | $214.6K | 76.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 3161 | $2.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.82 | 2228 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 3161 | 2.800 |
5 | 9017 | 2.790 |
5 | 15600 | 2.780 |
2 | 9863 | 2.770 |
2 | 44455 | 2.760 |
Price($) | Vol. | No. |
---|---|---|
2.820 | 2228 | 3 |
2.830 | 5600 | 3 |
2.840 | 5996 | 3 |
2.850 | 1681 | 3 |
2.860 | 3830 | 4 |
Last trade - 12.05pm 16/08/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online